Gilead Sciences, Inc. (GILD) Rating Reiterated by Leerink Swann
Leerink Swann reaffirmed their hold rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a report published on Tuesday morning. They currently have a $74.00 price objective on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued reports about the company. Piper Jaffray Companies reaffirmed a buy rating on shares of Gilead Sciences in a research report on Friday, April 21st. Vetr downgraded Gilead Sciences from a strong-buy rating to a buy rating and set a $74.88 price target on the stock. in a research report on Tuesday, April 25th. Stifel Nicolaus reaffirmed a buy rating and issued a $87.00 price target on shares of Gilead Sciences in a research report on Monday, April 24th. Jefferies Group LLC reaffirmed a buy rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, April 6th. Finally, Cowen and Company reaffirmed a buy rating and issued a $100.00 price target on shares of Gilead Sciences in a research report on Monday, April 17th. Thirteen equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of Buy and a consensus target price of $80.33.
Gilead Sciences (GILD) traded up 1.31% on Tuesday, hitting $75.94. The company had a trading volume of 8,954,646 shares. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $82.10. The firm’s 50 day moving average price is $69.98 and its 200 day moving average price is $68.63. The stock has a market cap of $99.18 billion, a P/E ratio of 8.25 and a beta of 1.21. Gilead Sciences also saw some unusual options trading on Wednesday. Stock investors purchased 23,892 put options on the stock. This is an increase of 241% compared to the typical daily volume of 7,005 put options.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue was down 8.2% compared to the same quarter last year. During the same period last year, the business posted $3.08 earnings per share. Equities analysts predict that Gilead Sciences will post $8.72 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-rating-reiterated-by-leerink-swann/1461361.html.
The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is currently 22.58%.
In related news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. In the last three months, insiders sold 128,276 shares of company stock valued at $9,190,610. 1.30% of the stock is currently owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the company. Parsec Financial Management Inc. raised its stake in Gilead Sciences by 4.7% in the second quarter. Parsec Financial Management Inc. now owns 82,913 shares of the biopharmaceutical company’s stock worth $5,869,000 after buying an additional 3,708 shares in the last quarter. Markel Corp raised its stake in Gilead Sciences by 22.2% in the second quarter. Markel Corp now owns 33,000 shares of the biopharmaceutical company’s stock worth $2,336,000 after buying an additional 6,000 shares in the last quarter. ST Germain D J Co. Inc. raised its stake in Gilead Sciences by 7.1% in the second quarter. ST Germain D J Co. Inc. now owns 4,006 shares of the biopharmaceutical company’s stock worth $284,000 after buying an additional 265 shares in the last quarter. Barry Investment Advisors LLC raised its stake in Gilead Sciences by 26.5% in the second quarter. Barry Investment Advisors LLC now owns 7,199 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 1,507 shares in the last quarter. Finally, Benedict Financial Advisors Inc. raised its stake in Gilead Sciences by 14.1% in the second quarter. Benedict Financial Advisors Inc. now owns 23,667 shares of the biopharmaceutical company’s stock worth $1,746,000 after buying an additional 2,922 shares in the last quarter. 74.05% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.